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Lung cancer is the most common fatal malignancy in the devel-
oped world and small-cell lung cancer (SCLC) comprises about
25% of these tumours. SCLC characteristically secrete a variety of
neuropeptides, such as adrenocorticotrophin hormone (ACTH),
gastrin-releasing peptide (GRP), gastrin, cholecystokinin and
arginine vasopressin (AVP). Many of these peptides can act as
autocrine growth factors (Woll, 1996). AVP is the peptide most
commonly secreted by SCLC, with up to 67% of tumours showing
immunoreactivity (Friedmann et al, 1994) and elevated plasma
concentrations (Maurer et al, 1983). In contrast, AVP production 
is rarely detected in non-neuroendocrine lung carcinomas
(Friedmann et al, 1993). Vasopressin receptors have been demon-
strated in SCLC (Fay et al, 1994; Coulson et al, 1997; North et al,
1998) and AVP is mitogenic for SCLC (Sethi and Rozengurt,
1991) suggesting that it can act as an autocrine factor promoting
proliferation in these tumours.
Physiological AVP expression is largely restricted to the hypo-
thalamus and is tightly regulated in response to plasma osmolality.
In contrast, the ectopic secretion of AVP by SCLC can be associ-
ated with the clinical syndrome of dilutional hyponatraemia
(Johnson et al, 1997). Because expression of AVP is so restricted
in normal tissue, and expression of AVP in SCLC does not respond
to osmolality, transcription from the AVP gene promoter in SCLC
may be uniquely tumour-specific. In other tumour types, tissue-
specific promoters have been used to drive expression of a
therapeutic gene (Huber, 1991; Vile and Hart, 1993), therefore we
propose that the AVP promoter could be exploited for targeting
gene therapy to SCLC.
Approximately 1.2-kb of the human AVP promoter region has
been sequenced (Bahnsen et al, 1992). The 200-bp sequence
immediately 5¢ to the coding region shows high cross-species
homology (Sausville et al, 1985; Hara et al, 1990) and some regu-
latory elements within this proximal promoter region have been
identified, for example those mediating cAMP responsiveness
(Verbeeck et al, 1991; Pardy et al, 1992). However, no elements
have yet been described which confer tissue-specificity on AVP
expression. Transgenic studies indicate that large regions of both
the 5¢ and 3¢ untranslated regions are required to mimic normal
hypothalamic AVP expression (Ang et al, 1993). The functional
human promoter might therefore extend further upstream than the
partially characterized proximal region, or contain alternative
SCLC-specific elements. We have isolated regions of the human
AVP promoter, and an enhancer, for evaluation of reporter gene
expression to determine the promoter elements relevant for tumour
expression. We have identified a short fragment of the AVP
promoter with strong activity in vitro and selectivity for SCLC cell
lines, which could be developed for targeting therapy to this
tumour type.
MATERIALS AND METHODS
Computer analysis
Sequence analysis software was accessed via the UK HGMP-RC,
Cambridge. Transcription factor binding sites within the AVP
promoter and gene were predicted using ‘Promoter Scan’
(Prestridge, 1995) and ‘Signal Scan’ (Prestridge, 1996).
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Figure 1 PCR amplification and cloning of human AVP promoter and enhancer elements. (A) Map of the AVP structural gene comprising the promoter, three
exons and two introns. (B) AVP promoter and enhancer fragments cloned from this region by PCR. The promoter, exon 1 and intron 1 are shown enlarged (top)
with the translational start codon at +56 relative to the transcriptional start site (+1). The PCR primer pairs and the promoter regions amplified are shown below,
the sizes given are for the cloned products. The VEN enhancer was amplified from the first intron by VENfor / VENrev (+1114 to +1429). (C) Additional
constructs (3¢ end at +42) were generated using restriction sites within the 1048-bp region, which is shown expanded (top). The BstX1 (–426), BanII (–86) and
BspM1(–23) sites represent the 5¢ ends of clones p468, p128 and p65 respectivelyIsolation of AVP promoter and enhancer regions
The AVP gene 5¢region and a potential enhancer within the first
intron were amplified from NCI-H510 (SCLC) genomic DNA. All
PCR primers were from Cruachem (Glasgow, UK) or MWG-
Biotech (Germany). Dynazyme II polymerase (Flowgen, Staffs,
UK) was used in optimized buffer (Flowgen) with 30 standard
PCR cycles and a final 10-min extension at 72°C to facilitate T/A
cloning. The primers VPFWD (5¢CAG ACA GGC CCA CGT
GTG 3¢) and VPREV (5¢CCT GGT GCA CAC AGG TGG ACC
3¢) amplified the proximal 199-bp fragment; VPP1 (5¢CCT CTT
TAG ACC TGC AAG CTT GGG 3¢) and VPP2 (5¢CCT GGT GCA
CAC AGG TCG ACC C 3¢) amplified a large fragment, of 1048bp
when cloned using the HindIII and AccI restriction sites engi-
neered into the primer sequences (underlined above). The primer
VP186for (5¢TG CCT GAA TCA CTG CTG ACG GC 3¢) was
used with VPREV to amplify a 186bp PCR product, and with
VPP2 to amplify a 186bp product containing an AccI site. The
enhancer was obtained using VENfor (5¢CTC TCC GCA TGG
TGT AGT GG 3¢) and VENrev (5¢TGC GGC TGC AGG CAC
GCT CG 3¢). The primer locations and products are shown in
Figure 1B.
Construction of reporter plasmids
The PCR products described above were ligated into a T/A cloning
vector derived from an EcoRV digest of pBluescript (Stratagene),
and their identity and sequence confirmed by automated
sequencing. No mutations relative to the previously published
sequences (Sausville et al, 1985; Bahnsen et al, 1992) were identi-
fied. Restriction sites, in the primers or plasmid, were utilized for
sub-cloning into chloramphenicol acetyl transferase (CAT)
reporter constructs. The promoterless (pnone) plasmid pBLCAT6
(a gift from Prof. Ian Hart, ICRF/Richard Dimbleby Labs,
St Thomas’ Hospital, London, UK) was used to clone the 5¢frag-
ments generating constructs with different lengths of promoter:
p1048, p199, p186 and p173. The plasmid p186MUT was derived
by cloning the 173 PCR product without using the internal AccI
site in the VPP2 primer. Additional constructs, p468, p128 and p65
(Figure 1C), were generated from p1048 by restriction digestion
with BstX1/HindIII, BanII/HindIII and BspM1/HindIII respec-
tively, then blunt-ended with T4 DNA polymerase (New England
Biolabs, Herts, UK) and ligated. The enhancer element was cloned
in the forward orientation into pBLCAT6 (promoterless) and
pBLCAT5 (containing a minimal thymidine kinase (tk) promoter)
to produce pVEN and pVENtk respectively. Plasmid pVEN468
was generated by sub-cloning of the VEN PCR product into p468
using the BstX1/HindIII sites, placing the enhancer upstream of
the intermediate length AVP promoter.
Cell lines and culture
The Lu-165 SCLC line was a gift from Dr T Terasaki (National
Cancer Centre, Tokyo, Japan), the non-SCLC (NSCLC) lines
MOR/P and COR-L23 were a gift from Dr P Twentyman (estab-
lished at the MRC Clinical Oncology Research Unit, Cambridge,
UK) and the SCLC line NCI-H711 was a gift from Dr B Johnson
(NCI, Bethesda, MD, USA). Other SCLC and NSCLC cell lines
originated from the ATCC. These cell lines were routinely main-
tained in RPMI–10% bovine calf serum (BCS) at 5% carbon
dioxide 37°C. Primary normal human bronchial epithelial cells
(NHBE) from a single donor (4653, Clonetics) and SV40 trans-
formed HBE (a gift from Dr W Franklin, University of Colorado
Cancer Centre, USA) were maintained in fully supplemented
Bronchial Epithelial Growth Medium (Clonetics) and used at the
third passage. All cells were used during exponential growth for
experiments.
Isolation of AVP mRNA from cultured cells and tissues
Total cellular RNA was prepared from 2 ´107 cultured cells using
a Purescript RNA kit (Gentra Systems Inc.) and prepared from
human hypothalamus using TRIzol (Life Technologies Inc.). The
concentration and integrity of all total RNA was determined.
Poly(A+) mRNA was isolated from 2 ´106 cultured cells using
Dynabeads mRNA Direct (Dynal) and resuspended in a volume of
50ml.
RT-PCR
For reverse transcription polymerase chain reaction (RT-PCR),
1mg of total cellular RNA was reverse transcribed (Promega, UK).
The cDNA was denatured and diluted to 100ml, 2ml of this was
used for PCR. Dynazyme II polymerase was used in magnesium-
free buffer (Flowgen) supplemented to a final concentration of
1mMmagnesium chloride. Glyceraldehyde-3-phosphate dehydro-
genase (GAPDH) primers (GAPDHfor: 5¢CCA ACC ATG GCA
AAT TCC ATG GCA 3¢/GAPDHrev: 5¢TCT AGA CGG CAG
GTC AGG TCC ACC 3¢, 28 cycles), which produce a band of 598
bp, were used as a control (Maier et al, 1990). AVP expression was
detected by standard or nested PCR. In the nested PCR, the first
round (25 cycles) with primers VPRNAfor (5¢TGC ATA CGG
GGT CCA CCT GT 3¢) and VPex2rev (5¢GTT GCA GCA AAC
GCC GAA GG 3¢) would generate a 348bp product. A 3ml
aliquot of this was then reamplified with two internal primers
VPRNAfor2 (5¢CAT GCT GCC CGC CTG CTT CC 3¢) and
VASrev (5¢TAG TTC TCC TCC TGG CAG C 3¢) which gener-
ated a 227bp product spanning intron 1. For the standard PCR
protocol, the primers VPRNAfor and VASrev generated a 269bp
product (35 cycles).
Northern blotting
Northern blots were prepared from glyoxal treated RNA.
Approximately 40mg of total RNA or the 50ml preparation of
poly(A+) RNA were loaded per lane. Gels were electrophoresed in
10mMsodium phosphate (pH 7.0) with recirculation of the buffer.
RNA was capillary transferred onto Hybond-N (Amersham), fixed
by ultraviolet (UV) irradation and baked at 80°C. The RNA
markers (Sigma) were stained with methylene blue. Random
primed probes were generated from double-stranded DNA, corre-
sponding to exon 1 of the AVP gene, and a cloned fragment of
GAPDH, using [a32P]dCTP and an oligolabelling kit (Pharmacia).
Blots were prehybridized for 2h in 6 ´sodium–saline citrate
(SSC), 1 ´Denhardts’ (0.2% Ficoll 400, 0.2% polyvinylpropyl-
ene, 0.2% BSA), 10mMsodium phosphate, 1mMEDTA pH 8.0,
5% dextran sulphate and 25mg ml–1 denatured salmon sperm
DNA; then hybridized with the probe at 65°C for 16h. Blots were
washed to 2 ´SSC and exposed to autoradiography film for 1 day
(GAPDH) and 6 or 55 days (AVP, for total and poly(A) blots
respectively).
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Intracellular AVP peptide was detected by immunocytochemistry.
Cultured cells were collected on Vectabond coated slides using a
cytospin, fixed in 1% paraformaldehyde and permeabilized with
70% ethanol. Cells were incubated with a primary polyclonal anti-
body AB1565 to AVP (Chemicon, Harrow, UK) at a dilution of
1 in 1000. This was visualized with a fluorescein isothiocyanate
(FITC)-conjugated anti-rabbit IgG (Sigma) and mountant
containing DAPI (Sigma) used to counterstain the nuclei.
Transient transfection of cell lines
A comparison of different transfection methods was undertaken
and electroporation selected as an effective method, allowing
detection of reporter gene expression in all the established cell
lines. Transfection efficiencies were estimated by the flow cytom-
etry method of Fiering et al (1991) to be around 3% in the SCLC
and NSCLC cell lines. Single-cell suspensions were prepared
either by manual disaggregation (suspension cells) or trypsiniza-
tion (adherent cells), 7.5 ´ 106 cells in a volume of 400 ml
RPMI–10% BCS, were used for transfection. An Easiject electro-
porator (Flowgen), settings: 260 V and 1050 mF (Baum et al,
1994), was used to deliver a total of 40 mg plasmid DNA. This
comprised 20 mg of test plasmid (AVP or SV40 promoter (pSV40)
coupled to a CAT reporter) and 20 mg of pSVbGal (Promega) to
control for transfection efficiency. Cells were transferred immedi-
ately to 20 ml of complete media. This method was used for all
cell lines with the exception of NHBE, which were transfected
using ExGen-500 (TCS Biologicals, Buckingham, UK). NHBE
were seeded in 6-well plates at 4 ´ 105 cells per well 24 h prior to
transfection. Cells were treated with 10 ml ExGen-500 and 2 mg
DNA per well in fresh growth media, incubated for 2 h and media
replaced.
Reporter gene assays
Cells were transfected with the reporter constructs as described
above, and harvested after a 72-h expression period, in 500 ml of
lysis buffer. The protein content of lysates was determined using
an ESL protein assay (Boehringer) to confirm yields of cells. CAT
and  b-galactosidase (bGal) reporter activity were determined
using the respective enzyme-linked immunosorbent assay
(ELISA) kits (Boehringer) and absorbance converted to pg of
enzyme from a standard dilution series. Levels of CAT were calcu-
lated as a ratio to pSVbGal reporter expression to standardize for
transfection efficiency.
RESULTS
Cloning of the AVP promoter and enhancer regions
Although 1.2 kb of the 5¢ promoter region for human AVP has
been cloned and sequenced (Bahnsen et al, 1992), this has been
only partially characterized and no SCLC-specific elements have
been identified. We amplified this region by PCR, as described in
detail in Methods and shown diagrammatically in Figure 1B. A
1048-bp fragment (–1006 to +42) of the human AVP 5¢ region was
cloned using HindIII and AccI sites generated by the primers, this
was used to drive expression of a CAT reporter gene. Promoter
constructs corresponding to the partially characterized 199-bp
1938 JM Coulson et al
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Figure 2 AVP mRNA expression in cultured cells. AVP expression was
determined in human hypothalamus (Hypo), five SCLC cell lines and seven
control cell lines: NCI-H460, COR-L23, MOR/P (all NSCLC), NHBE and
SV40-HBE (bronchial epithelial cells), HL60 (promyelocytic leukaemia) and
Cos-7 (SV40 transformed monkey kidney fibroblasts). (A) RT-PCR analysis.
Nested PCR with primers specific for AVP (above), GAPDH PCR (below).
(B) Northern analysis of total RNA, shown hybridized with a probe
representing exon 1 of the AVP gene (above), which detected a single
transcript of 795-bp. The blot was reprobed for the 1.4-kb GAPDH mRNA
(below). (C) Northern analysis of poly(A) RNA, shown hybridized with for AVP
(above) and GAPDH (below) as described for (B)region (Figure 1B) and an intermediate 468-bp fragment
(Figure 1C), were also cloned for initial experiments.
A region with a high density of transcription factor binding
sites, which lacked a TATA box, was identified within the first
intron of the human AVP gene by computer analysis. We hypothe-
sized that this region (VEN, Figure 1B) might represent an
enhancer element and confer additional tissue-specificity in
combination with the 5¢ promoter. This was cloned into reporter
constructs (as described in Methods) for analysis of enhancer
activity in combination with the AVP and tk promoters.
Detection of AVP expression in lung cancer cell lines
A panel of SCLC and control cell lines was screened for AVP
mRNA expression by RT-PCR and Northern analysis (Figure 2).
In a 35-cycle standard PCR reaction, an AVP-specific band was
only detected in the hypothalamus control and the Lu-165 SCLC
line (data not shown). However, by the highly sensitive, but non-
quantitative nested RT-PCR method, an AVP-specific PCR
product of 227 bp was detected in all the SCLC lines (Figure 2A).
This was most intense in the Lu-165 line and identical to that
amplified from hypothalamic cDNA. The product was absent in
three non-neuroendocrine NSCLC and other control cell lines,
including human bronchial epithelial cells. Hybridization of a
Northern blot prepared from total RNA, with a probe specific to
the first exon of AVP, demonstrated high levels of the AVP tran-
script in the Lu-165 cell line alone (Figure 2B). An identical result
was obtained for a poly(A+) mRNA blot prepared from these cells
(Figure 2C). These data are in agreement with the results described
for the standard RT-PCR protocol. We also examined AVP peptide
in the SCLC cell lines by immunocytochemistry. Abundant
peptide was seen in the cytoplasm of Lu-165 cells (Figure 3),
consistent with earlier reports of peptide secretion (Terasaki et al,
1994), while less intense staining was apparent in the other SCLC
lines studied.
Therefore, although AVP mRNA was present in all the SCLC
lines tested, the level of mRNA and peptide expression was
markedly elevated only in the Lu-165 line. These cells were previ-
ously reported to contain 100-fold more AVP peptide than other
SCLC lines, such as NCI-H69 by radioimmunoassay (Terasaki et
al, 1994). The other SCLC lines expressed low levels of AVP, only
detectable by nested PCR, this included NCI-H711, which were
originally reported to show high AVP secretion (Gross et al, 1993).
However, these findings are consistent with previous observations
that high AVP expression, while common in SCLC tumours
(Friedmann, 1994), is less common in SCLC lines cultured in vitro
(Verbeeck et al, 1992; Gross et al, 1993). It was evident that
SCLC-specific vasopressin promoter activation 1939
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Figure 3 AVP peptide expression in Lu-165 cells (magnification ´ 500). 
(A) Immunocytochemistry showing detection of the cytoplasmic peptide. 
(B) Nuclei counterstained with DAPI
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Figure 4 Relative reporter gene expression in transiently transfected cells. (A) The series of three CAT reporter constructs based on the AVP 5¢ promoter, SV40
promoter (positive control), reverse orientation AVP promoter and promoterless construct (negative controls). These are illustrated to the left of the
corresponding experiments. (B) Reporter activity is shown for three representative cell lines: Lu-165 (SCLC, high AVP expression), NCI-H345 (SCLC, low AVP
expression) and COR-L23 (NSCLC, no detectable AVP expression). Data are expressed relative to pSV40 (+/– 1 s.d., n = 3)transcription of AVP was markedly SCLC-specific, as no tran-
script was detected in normal lung epithelium, NSCLC or the other
tumour cell lines tested. This panel of cell lines, for which we have
characterized endogenous transcription, was used to evaluate
reporter gene expression from the cloned AVP promoter.
Characterization of the AVP promoter
The AVP promoter/CAT reporter plasmids described are repre-
sented diagrammatically in Figure 4A. These were co-transfected
with pSVbGal to control for transfection efficiency and relative
reporter gene expression data are shown for ten cell lines and
NHBE in Table 1. All three fragments of the AVP promoter were
active in all the SCLC lines. Although the intermediate 468-bp
region showed slightly higher activity in the majority of SCLC
lines, the large promoter fragments contributed no significant
enhancer activity. The promoterless vector and the reverse orienta-
tion control had no reporter expression.
In addition, the level of promoter activity in the SCLC cell lines
reflected their normal transcriptional activity (Figure 2). High
level expression was seen in the Lu-165 cell line, which ranged
from 3.1- to 4.9-fold greater than that obtained with the SV40
1940 JM Coulson et al
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Table 1 CAT reporter expression in transiently transfected cell lines
Cell Type AVP p1048
line RNA pSV40 pnone p199 p468 p1048 rev
GLC-19 SCLC + 0.14 –0.26 0.45 0.57 0.35 –0.10
(0.14) (0.35) (0.09) (0.08) (0.14) (0.08)
NCI-H69 SCLC + 0.60 0.00 0.35 0.24 0.23 0.00
(0.10) (0.00) (0.11) (0.06) (0.03) (0.01)
NCI-H345 SCLC + 0.28 0.00 0.15 0.18 0.15 0.00
(0.08) (0.01) (0.01) (0.07) (0.05) (0.02)
NCI-H711 SCLC + 0.33 –0.01 0.13 0.16 0.09 –0.01
(0.08) (0.01) (0.06) (0.07) (0.03) (0.01)
Lu-165 SCLC +++ 1.49 –0.18 4.63 7.33 5.51 –0.15
(0.60) (0.06) (0.9) (0.5) (1.6) (0.0)
NCI-H460 NSCLC – 4.11 0.00 0.00 0.00 –0.01 –0.02
(0.94) (0.00) (0.01) (0.00) (0.01) (0.01)
MOR/P NSCLC – 0.50 0.00 0.00 0.00 0.00 0.00
(0.11) (0.00) (0.00) (0.00) (0.00) (0.00)
COR-L23 NSCLC – 0.59 0.00 0.00 0.00 0.00 0.00
(0.24) (0.00) (0.01) (0.01) (0.01) (0.00)
NHBE Lung control – 1.41 ND ND 0.07 ND ND
(1.69) (0.09)
HL60 Suspension control – 0.94 0.03 0.06 0.05 0.05 0.04
(0.39) (0.01) (0.03) (0.03) (0.03) (0.02)
Cos-7 Transfection control – 1.08 0.01 0.07 0.12 0.11 0.01
(0.06) (0.01) (0.04) (0.01) (0.01) (0.01)
Cells were co-transfected with pSVbGal and either the AVP promoter fragments or an SV40 promoter (pSV40) coupled to the CAT reporter gene. Reporter
activity was determined by ELISA as pg ml–1 of each enzyme. Levels of CAT were calculated as a ratio to pSVbGal reporter expression to standardize for
transfection efficiency, so promoter activity is expressed as CAT:bGal activity. n = 3 for all data (+/– 1 s.d.). ND, not done.
SCLC NSCLC
Lu-165 H69 COR-L23
1 5 10 15
Relative enhancer activity
tk promoter CAT
ptk
pVENtk
p468
pVEN468
VEN
AVP promoter
VEN
AB
Figure 5 Relative activity of an enhancer. (A) The VEN enhancer region was coupled to the AVP promoter (p468) or a minimal tk general promoter (ptk), these
CAT reporter constructs are shown to the left of corresponding experiments. (B) Relative enhancer activity in cell lines with varying levels of endogenous AVP
expression: Lu-165 (very high), H69 (very low) and COR-L23 (not detected). The mean data for reporter gene expression of each promoter alone (p468 or ptk)
is normalized to 1, or represented as 0 if inactive. Enhancer activity is shown relative to the basic promoter activity (+/– 1 s.d., n = 3)promoter (Figure 4B). The NCI-H345 SCLC line has lower but
clearly detectable AVP mRNA expression (Figure 2A), and the
AVP promoter activity was only around half that of the SV40
promoter in these cells. In the NSCLC NCI-H460 cell line (Figure
4B), these AVP promoter fragments were inactive. Indeed in all
the AVP-negative lines tested, including NHBE cells, the SV40
promoter was active, whereas the AVP 468-bp promoter had negli-
gible activity (Table 1). Strikingly, even the p199 fragment was
able to confer tumour-specificity on gene expression in the panel
of cell lines tested.
Additional experiments using a cytomegalovirus (CMV)
promoter/bGal reporter to standardize the data yielded similar
results. CAT expression for p199 and p1079rev normalized to
pSV40 was 2.26 and 0.00 respectively in Lu-165 cells, compared
to 0.00 and –0.01 in NCI-H460. Comparable results (of 0.59 and
0.05 for p199 and p1079rev respectively) were also obtained in the
NCI-H69 cell line on co-transfecting with the plasmid pRL-CMV
and detection of Renilla luciferase by the dual-luciferase assay
(Promega), indicating the results are independent of the co-trans-
fection plasmid. The transfection protocol had no influence on
SCLC-specific vasopressin promoter activation 1941
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Table 2 Relative enhancer activity in transiently transfected cell lines
Cell line Type AVP ptk pVENtk/ptk p468 pVEN468/p468
GLC-19 SCLC + 1 2.39 (s.d. = 0.79) 1 ND
NCI-H69 SCLC + 1 6.00 (s.d. = 7.33) 1 2.80 (s.d.=0.56)
NCI-H345 SCLC + 1 2.94 (s.d. = 0.59) 1 ND
NCI-H711 SCLC + 1 4.68 (s.d. = 0.83) 1 2.54 (s.d.=1.22)
Lu-165 SCLC +++ 1 7.90 (s.d. = 1.49) 1 2.90 (s.d.=0.21)
NCI-H460 NSCLC – 1 21.8 (s.d. = 0.86) 1 0.00 (s.d.=0.00)
MOR/P NSCLC – 1 36.0 (s.d. = 3.00) 1 ND
COR-L23 NSCLC – 1 9.00 (s.d. = 6.00) 1 0.00 (s.d.=0.00)
NHBE Lung control – 1 ND 1 ND
HL60 Suspension control – 1 1.50 (s.d. = 0.14) 1 ND
Cos-7 Transfection control – 1 6.25 (s.d. = 3.50) 1 ND
Activity of the enhancer from intron 1 of the AVP gene in the panel of cell lines. Activity of enhancer constructs (VEN) is shown relative to the same promoter in
the absence of the enhancer, either ptk (minimal thymidine kinase general promoter) or p468 (AVP promoter expressed in SCLC only). n = 3 +/– 1 s.d. ND, not
done.
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Figure 6 Investigation of the AVP promoter elements required for restricted expression. (A) The proximal AVP promoter showing putative E-box and other
transcription factor binding sites (top). The location of these sites, within the parent p199 reporter construct, further 5¢ deletions and other modifications of this
construct, are shown below. The TATA box is located at –23, potential CRE, AP-1, AP-2 and four E-box sites are illustrated, other potential AP-2 sites coincide
with E-box B, the CRE and AP-2 site shown. The constructs p199, p173, p128 and p65 represent –157, –131, –86 and –23 to +42 respectively; p186 and
p186MUT (mutation in E box D at +40) represent –131 to +56. (B) Histogram showing the relative CAT reporter activity from these constructs following
transfection into Lu-165 cells, the activity of p199 is represented as 100% (+/– 1 s.d., n = 3)reporter gene expression as calcium phosphate precipitation,
which efficiently transfected NCI-H69, yielded similar results to
those obtained by electroporation in this cell line (data not shown).
Characterization of a potential enhancer
We confirmed that the VEN region lacked intrinsic promoter
activity in the promoterless construct pVEN, where the ratio of
CAT to bGal expression (n = 3) was zero in both the Lu-165 and
NCI-H460 cell lines. However, when VEN was coupled to other
promoters (Figure 5A) it was shown to enhance transcriptional
activity of the general tk promoter in all cell lines tested (Table 2).
Transcription was increased by two- to eight-fold in the SCLC
lines and was elevated to an even greater extent in the NSCLC
lines, ranging from nine- to 36-fold; representative examples are
shown in Figure 5B. However, when coupled to the AVP
promoter, the enhancer was only active in SCLC lines, increasing
transcription by two- to three-fold. The AVP promoter remained
inactive in the NSCLC lines, such as COR-L23 (Table 2 and
Figure 5B), even in combination with this strong enhancer.
Therefore, although not itself tumour-specific, the VEN region
does not override restricted expression when coupled to the AVP
promoter. Interestingly, it substantially increases transcription in
SCLC lines, such as NCI-H69 (Figure 5B), where endogenous
AVP expression is very low (Figure 2A).
Further analysis of the 5¢ promoter
In contrast to the putative enhancer, the AVP 5¢ region only
directed strong expression in a SCLC line with high endogenous
AVP. We analysed the entire 5¢ promoter sequence for transcrip-
tion factor binding motifs using ‘Signal Scan’. This showed
previously reported elements and a number of other potentially
important sites. The sites of interest are illustrated in Figure 6A
and include AP-1, AP-2 and E-box motifs. The AP-2 sites and
cAMP responsive element (CRE) are seen in the homologous
region of the rat promoter (Iwasaki et al, 1997). There is a high
density of E-box motifs within this region, some of which bind
proteins in the rat AVP promoter (Grace et al, 1999).
To elucidate the regulatory elements between –157 and +42,
which are involved in the pathological activation of the human
AVP promoter in SCLC, we generated additional 5¢ deletion
constructs, illustrated in Figure 6A. Two E-box motifs (A and B)
are located at the 5¢ end of the 199 bp fragment, adjacent to an AP-
1 site with which they may interact. The p173, p186, p186MUT
plasmids all lack E-boxes A and B, while p186 (–131 to +56)
includes an additional E-box (D) 3¢ to the transcriptional start site.
The construct p128 contains only E-box C and p65 represents the
minimal promoter.
Reporter gene expression from these plasmids, in transiently
transfected Lu-165 cells, is shown in Figure 6B. It is clear that
while the loss of E-boxes A and B (p173) results in a reduction of
AVP promoter activity to approximately 25% of that for p199, this
is still equivalent to the SV40 promoter activity. E-boxes C and D
appear to have little influence on promoter activity in this cell line,
although in p128, where sequences adjacent to C are removed, the
activity increases approximately twofold. This partially restored
activity in p128 implies a repressor function within the region
–131 to –86. Clearly, some of these elements are involved in
modulating expression, and at least some of the E-box motifs
increase promoter activity. However, none of these elements are
essential for tumour-specificity as none of the deletion constructs
described were active in the NSCLC control cell line (data not
shown). The minimal p65 promoter, encompassing only the basic
transcriptional machinery, retains specificity.
DISCUSSION
We have demonstrated that short fragments of the human AVP 5¢
promoter are sufficient to direct strong, highly SCLC-specific
gene expression in vitro. This mimics the activity of the endoge-
nous AVP promoter in a panel of cell lines and the essential regu-
latory elements are localized between –157 and +42 in the human
promoter. Additional sites present between –426 and –157 may
account for the marginally increased activity associated with an
intermediate fragment, whilst the inclusion of further sequence up
to –1006 conveys no additional activation, and may encompass
some repressor activity. It was recently reported that elements
mediating osmotic and endothelin 3 regulation of the rat AVP
promoter may be present between –1500 and –532 (Kim et al,
1996) and a hyperosmolarity responsive element is predicted 
at –355 in the human AVP promoter (Okazaki et al, 1997).
Repressors are likely to play a role in restricting expression, and a
glucocorticoid repressor element has been localized to between
–300 and –155 in a bovine transgene (Burke et al, 1997). In each
case, the homologous regions of the human promoter lie outside
the 199-bp promoter construct described here. It therefore is
unlikely that any of these elements are involved in SCLC-specific
expression, although indirect glucocorticoid repression has been
described in the proximal rat AVP promoter (Iwasaki et al, 1997).
Several neuronal transcription factors involved in determination
of cell lineage, have been identified as candidate SCLC-specific
factors. Those implicated in control of neuropeptide expression
belong to two main groups, the POU-domain and the basic
helix–loop–helix (bHLH) families. Three E-boxes are common to
the cloned fragments initially evaluated and may be involved in
binding bHLH factors. Human achaete-scute homologue 1 (hASH-
1) is a bHLH factor, which is not expressed in normal adult tissue,
but has been shown in neuroendocrine tumours including SCLC
(Ball et al, 1993) and as such represents a candidate SCLC-specific
factor. Therefore, it was hypothesized that the E-box motifs in the
AVP promoter may be bound by such a bHLH SCLC-specific tran-
scription factor, resulting in the AVP expression seen in SCLC.
Interestingly, since this manuscript was submitted, an E-box
(CACGTG) in the mouse AVP promoter has been reported to
control circadian expression in the suprachiasmatic nuclei (Jin et
al, 1999). This corresponds to the human E-box A described here
and lends support to our suggestion that it represents a potential
tissue-specific enhancer. E-boxes A and B are also adjacent to an
AP-1 site, and synergy between AP-1 and E-box sites has been
suggested to contribute to tissue-specific regulation (Quinn, 1996;
Yoon and Chikaraishi, 1992). Our data indicate that although some
E-box motifs are used, additional repressor elements within the
minimal promoter (p65) are essential for SCLC-specificity, and a
pattern of both positive and negative regulation operates, as
described already for other neuropeptide promoters (Quinn, 1996).
We have also described a non-selective intronic enhancer
region. The activity of this sequence may be attributable to the
predicted presence of Sp1 and AP-2 sites. This region was not
SCLC-specific and in fact, was shown to act as a strong enhancer
in the NSCLC line. Interestingly though, when the enhancer was
coupled to the 468 bp AVP promoter this remained inactive in the
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promoter. The ability of the enhancer to increase transcription
when coupled to the AVP promoter in a SCLC cell line with low
endogenous AVP production (H69) implies, that although this may
not naturally be a functional enhancer of the AVP promoter, it
represents a useful tool in producing a synthetic promoter
construct to target SCLC.
Our findings have potential applications in targeting gene
therapy, for example to express suicide genes in a prodrug
approach. Other studies have analysed the myc-mad response
element (Kumagai et al, 1996) and the CD24 promoter (Pass et al,
1998) as potential SCLC-specific promoters. However, both these
approaches have inherent drawbacks and neither is likely to prove
as highly SCLC-specific as the AVP promoter. The myc-mad
response element is an E-box motif of the specific sequence
CACGTG. This is the same sequence as the E-box motif A within
the AVP promoter (Figure 6A), which may enhance, but not
restrict, expression in our system. In addition Myc is expressed in
all cells and CD24 is highly expressed in neutrophils.
Whilst small amounts of AVP may be synthesized elsewhere
(Murphy et al, 1993), physiological expression is essentially
restricted to the hypothalamus and ectopic production by SCLC in
vivo is higher than in vitro. Therefore, anti-tumour treatments
targeted at AVP expressing cells would be predicted to have few
systemic side-effects. An attraction of the AVP promoter model is
that hypothalamic mRNA expression can be reduced by giving a
fluid load, protecting the organ from SCLC-directed cytotoxic
therapy. Alternatively, replacement therapy is already available,
should hypothalamic damage occur. Therefore the AVP promoter
is a valuable tool for designing therapies targeted to SCLC.
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